Scarica l'app Stockscreener
12.71
0.24%
0.010
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
FDMT4D Molecular Therapeutics Inc Revenue Breakdown - Finviz
Price to earnings forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan - Stock Titan
Form 144 4D Molecular Therapeutics For: 30 June By Investing.com - Investing.com Canada
FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720 - Stock Titan
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - The Manila Times
4DMT to present 2-year PRISM trial follow-up at retina meeting - Stock Titan
H.C. Wainwright reiterates Buy on 4D Molecular stock on trial progress By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
4D Molecular Therapeutics Shares Rise After New Credit Facility - Moomoo
4D Molecular Therapeutics secures $200M credit facility - Investing.com
4D Molecular (FDMT) Completes Enrollment for Phase 3 Clinical Tr - GuruFocus
4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd - marketscreener.com
4D Molecular Therapeutics Secures Strategic Credit Facility for Up to $200 Million from Hercules Capital - marketscreener.com
4D Molecular Therapeutics secures $200M credit facility By Investing.com - Investing.com Australia
4D Molecular Therapeutics Secures $200 Million Loan Facility - TipRanks
4D Molecular Therapeutics Secures Up to $200 Million Term Loan Facility From Hercules Capital - TradingView
4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules - Stock Titan
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - GlobeNewswire
4D Molecular Therapeutics, Inc. Actuals & Estimates (NASDAQ:FDMT) - TradingView
Strength seen in 4D Molecular Therapeutics (FDMT): Can its 7.9% jump turn into more strength? - MSN
4d molecular therapeutics CLO Scott Bizily sells $117,720 in stock - Investing.com UK
Form 4 4D Molecular Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria
4d molecular therapeutics CLO Scott Bizily sells $117,720 in stock By Investing.com - Investing.com Australia
4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12 - Stock Titan
FDMT Forecast — Price Target — Prediction for 2027 - TradingView
Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap - Barchart.com
Form 144 4D Molecular Therapeutics For: 23 June By Investing.com - Investing.com South Africa
4d molecular therapeutics CEO David Kirn sells $1.2m in stock - Investing.com UK
4d molecular therapeutics CEO David Kirn sells $1.2m in stock By Investing.com - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Insider Sell Alert: David Kirn Sells 114,746 Shares of 4D Molecu - GuruFocus
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares - Stock Titan
4D Molecular Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kirn David - Moomoo
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Yahoo Finance
4D Molecular Therapeutics, Inc. announced that it expects to receive $200 million in funding - marketscreener.com
Form 144 4D Molecular Therapeutics For: 22 June By Investing.com - Investing.com Nigeria
David Kirn reports sale of 1,922 FDMT shares via Goldman Sachs (FDMT) - Stock Titan
4D Molecular Therapeutics Stockholders Back Directors and Governance - TipRanks
4D Molecular Therapeutics stockholders elect directors and approve proposals at annual meeting - Investing.com Australia
Form 8K 4D Molecular Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics (NASDAQ: FDMT) investors approve directors, auditor and pay - Stock Titan
4D Molecular Therapeutics (FDMT) AGM 2026 Summary - Quartr
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):